Indivior Pharmaceuticals (INDV) Cost of Revenue (2024 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Cost of Revenue of $40.0 million for Q1 2026, down 9.09% year-over-year from $44.0 million in Q1 2025, and down 40.3% quarter-over-quarter from $67.0 million in Q4 2025.
Indivior Pharmaceuticals (INDV) Cost of Revenue (2024 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Cost of Revenue history runs 3 years deep, the most recent figure standing at $40.0 million for Q1 2026.
- In Q1 2026, Cost of Revenue fell 9.09% year-over-year to $40.0 million; the TTM figure through Mar 2026 stood at $242.0 million (up 2.11% YoY), while the FY2025 annual figure was $246.0 million, up 6.49% from the prior year.
- Cost of Revenue for Q1 2026 stood at $40.0 million, down from $67.0 million in the prior quarter.
- The five-year high for Cost of Revenue was $83.0 million in Q3 2025, with the low at $38.0 million in Q1 2024.
- The 3-year median for Cost of Revenue is $52.0 million (2025), against an average of $57.4 million.
- Peak annual rise in Cost of Revenue reached 39.58% in 2025, while the deepest fall reached 34.18% in 2025.
- Indivior Pharmaceuticals' Cost of Revenue stood at $48.0 million in 2024, then soared by 39.58% to $67.0 million in 2025, then tumbled by 40.3% to $40.0 million in 2026.
- Business Quant data shows INDV's Cost of Revenue at $40.0 million in Q1 2026, $67.0 million in Q4 2025, and $83.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Indivior Pharmaceuticals | 4.60 Bn | 4.38 Bn | 294.00 Mn | 50.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.00 Mn |
| Jun 30, 2026 | 50.00 Mn |
| Mar 31, 2026 | 40.00 Mn |
| Mar 31, 2026 | 40.00 Mn |
| Dec 31, 2025 | 67.00 Mn |
| Dec 31, 2025 | 67.00 Mn |
| Sep 30, 2025 | 83.00 Mn |
| Sep 30, 2025 | 83.00 Mn |
| Jun 30, 2025 | 52.00 Mn |
| Jun 30, 2025 | 52.00 Mn |
| Mar 31, 2025 | 44.00 Mn |
| Mar 31, 2025 | 44.00 Mn |
| Dec 31, 2024 | 48.00 Mn |
| Dec 31, 2024 | 48.00 Mn |
| Sep 30, 2024 | 66.00 Mn |
| Sep 30, 2024 | 66.00 Mn |
| Jun 30, 2024 | 79.00 Mn |
| Jun 30, 2024 | 79.00 Mn |
| Mar 31, 2024 | 38.00 Mn |
| Mar 31, 2024 | 38.00 Mn |